Page 2 - Alkermes News Today

Shares of Alkermes plc (NASDAQ:ALKS – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ten analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have given a buy recommendation to […]

- Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - -

Alkermes (NASDAQ:ALKS – Free Report) had its price objective increased by Cantor Fitzgerald from $43.00 to $48.00 in a research report report published on Thursday morning, Benzinga reports. The brokerage currently has an overweight rating on the stock. Several other research analysts also recently commented on ALKS. HC Wainwright reaffirmed a neutral rating and issued […]

Dimensional Fund Advisors LP grew its stake in Alkermes plc (NASDAQ:ALKS – Free Report) by 3.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,403,195 shares of the company’s stock after buying an additional 90,219 shares during the period. Dimensional Fund […]

Investors should take a close look at these biotech stocks as they position themselves to provide high returns.

The deal is the second acquisition for CG Life this year, following the addition of Toolhouse in March.

A new patient-centric data platform has been launched to enhance research on central disorders of hypersomnolence.

StockNews.com lowered shares of Alkermes (NASDAQ:ALKS – Free Report) from a buy rating to a hold rating in a research note released on Friday. ALKS has been the topic of a number of other reports. Robert W. Baird started coverage on Alkermes in a research note on Tuesday, March 19th. They issued an outperform rating […]

HC Wainwright reissued their neutral rating on shares of Alkermes (NASDAQ:ALKS – Free Report) in a report published on Thursday morning, Benzinga reports. They currently have a $35.00 price objective on the stock. A number of other equities analysts also recently commented on the stock. StockNews.com downgraded shares of Alkermes from a strong-buy rating to […]

Alkermes (NASDAQ:ALKS – Get Free Report) released its quarterly earnings data on Wednesday. The company reported $0.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.15), Briefing.com reports. Alkermes had a net margin of 25.17% and a return on equity of 20.31%. The firm had revenue of $350.37 million […]